MapLight Therapeutics Partners with Flex Databases to Streamline Clinical Operations with Integrated CTMS and eTMF Platform

March 26, 2026 - MapLight Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for patients with difficult-to-treat CNS disorders, today announced its selection of Flex Databases as its primary provider for Clinical Trial Management System (CTMS) and electronic Trial Master File (eTMF) solutions.

As MapLight continues to advance its clinical pipeline, the company sought a unified platform capable of enhancing oversight, ensuring regulatory compliance, and providing real-time data access across multiple global programs.

Efficiency Through Integration

The decision to transition to Flex Databases was driven by the need for a seamless, integrated ecosystem. By combining CTMS and eTMF into a single platform, MapLight reduces the administrative burden of managing disparate systems.

"We liked the fact that Flex Databases offers an integrated CTMS and eTMF system, as it means less overall work to implement and manage," the MapLight team shared. "This strategy enables us to use our own CTMS for monitoring activities, giving us real-time access to data while leveraging CROs for our drug development activities."

Solving Compliance and Data Integrity Challenges

MapLight identified several critical areas where Flex Databases outperformed previous providers:

• GDPR Compliance: Flex Databases provides a "turnkey" solution for stringent GDPR requirements, ensuring the privacy of research participants is maintained at every stage.

• Advanced TMF Functionality: The system addresses previous gaps in document management, specifically through automated duplicate document detection and robust Quality Control (QC) reporting.

• Configurability: The CTMS is designed to be highly configurable, allowing the MapLight team to extract precise data points required for effective study oversight from startup to closeout.

A Vision for Long-Term Clinical Strategy

Beyond technical features, MapLight selected Flex Databases based on the potential for a long-term partnership. The platform will serve as a central repository for historical information, allowing the company to analyze past performance to more effectively plan future trials.

"We look for vendor teams that are supportive, proactive, and willing to listen to and act on feedback," MapLight stated. "The Flex Databases platform will provide a great source of historical information that will enable us to plan new trials effectively."

About MapLight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company that combines cutting-edge neuroscience with drug discovery to develop targeted therapies for patients with central nervous system (CNS) disorders. Their mission is to improve the lives of those suffering from conditions where current treatment options are limited.

About Flex Databases

Flex Databases is a managed software-as-a-service (SaaS) provider specializing in eClinical solutions. Their platform offers a comprehensive suite of modules, including CTMS, eTMF, Pharmacovigilance, and LMS, designed to bring efficiency and transparency to the clinical trial process.